From:  Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences

List of ADCs that have entered the clinical evaluation for lymphoma patients, sorted by their target and by their official name, if assigned, or by their common/alternative name

TargetAliasDevelopment codesLinkerPayloadPayload targetClinical stage*Orphan drug status (if any)*Development stage*Key AEs
CD19Coltuximab ravtansine [111, 188]SAR3419, huB4-DMSPDB (C)DM4Microtubules2-No on-going trialsIRR, ocular toxicity±, gastrointestinal toxicity†, peripheral neuropathy
Denintuzumab mafodotin [112, 189]SGN-CD19A, SGN-19A, hBU12-491Maleimidocaproyl (NC)MMAFMicrotubules2-No on-going trialsOcular toxicity±
Loncastuximab tesirine [113, 115, 121]ADCT-402, RB4v1.2- SG-3249Val-Ala (C)PBD (SG3199)DNAAppr.MCL, DLBCLOn-going trialsIRR, thrombocytopenia, neutropenia, cutaneous toxicity, edema/effusion
CD20-MT-3724 [190–193]Ab directly fused to toxinShiga-like toxin-I A1Ribosomes2-No on-going n.a. trials
CD22Inotuzumab ozogamicin [133, 194, 195]CMC-544, PF-5208773, WAY-2072944-(4-acetylphenoxy) butanoic acid (C)CalicheamicinDNA2Precursor cell lymphoblastic leukemia-lymphomaOn-going trialsIRR‡, neutropenia, febrile, thrombocytopenia, anemia, gastrointestinal toxicity†, hepatotoxicity§, pancreatitis/ lipase elevation, veno-occlusive disease/sinusoidal obstruction syndrome, hemorrhagic events, tumor lysis syndrome
Pinatuzumab vedotin [132, 149]DCDT2980S, RG-7593, ACD22- VCMMAE, FCU-2703, RG-7593, RO-5541072Val-Cit (C)MMAEMicrotubules2-No on-going trialsIRR‡, neutropenia, peripheral neuropathy, gastrointestinal toxicity†, hyperglycemia
Moxetumomab pasudotox [136, 196]RFB4[GTHW] , (dsFv)-PE38, HA22, CAT- 8015-Pseudomonas exotoxin A (PE38)Protein synthesisAppr.HCLOn-going trialsIRR, gastrointestinal†, edema, anemia, hypophosphatemia, headaches, hemolytic uremic syndrome, capillary leak syndrome
Epratuzumab- cys-tesirine [135]ADCT-602, Epratuzumab-cys-SG3249, hLL2-cys-PBD, hLL2-cys-SG3249Val-Ala (C)PBD (SG3199)DNA2-On-going trialsn.a.
-TRPH 222, CAT-02-106 [134, 140]SMARTag (NC)MaytansinoidMicrotubules1-On-going trialsn.a.
CD25Camidanlumab tesirine [155, 157, 158, 197, 198]ADCT-301Val-Ala (C)PBD (SG3199)DNA2-On-going trialsIRR, gastrointestinal†, anemia, hepatotoxicity, skin, edema, headache, immune system disorder and multiple cranial nerve palsy
CD30Brentuximab vedotin [66, 68, 76, 199–202]SGN-35, cAC10- vcMMAEVal-Cit (C)MMAEMicrotubulesAppr.HL, ALCL, PTCL, CTCLOn-going trialsIRR‡, gastrointestinal toxicity†, neutropenia, thrombocytopenia, peripheral neuropathy, hyperglycemia, pancreatitis/ lipase elevation, pneumonitis, hepatotoxicity§, JCV-induced progressive multifocal leukoencephalopathy
-F0002-ADC, anti-CD30- MCC-DM1 [94]SMCC (NC)DM1Microtubules1-On-going trialsn.a.
CD37Naratuximab emtansine [161, 162, 166]Debio 1562, IMGN529SPDB (C)DM4Microtubules2DLBCLNo on-going trialsIRR, gastrointestinal toxicity†, febrile neutropenia, thrombocytopenia, tumor lysis syndrome
-AGS67E [203, 204]Maleimidocaproyl- Val-Cit-PABC (C)MMAEMicrotubules1-No on-going trialsn.a.
CD70-MDX-1203, BMS936561 [205, 206]Val-Cit (C)Duocarmycin (MED-2460)DNA1-No on-going trialsn.a.
Vorsetuzumab mafodotin [207]SGN-75, h1F6- mcMMAFVal-Cit (C)MMAEMicrotubules1-No on-going trialsn.a.
-SGN-CD70A, SGN 70A [169]Maleimidocaproyl 1 (NC)MMAFMicrotubules1-No on-going trialsn.a.
CD71-CX-2029, ABBV-2029 [20, 172]Val-Cit (C)MMAEMicrotubules2-On-going trialsn.a.
CD79BPolatuzumab vedotin [28, 96, 98, 149]DCDS4501A, RG7596, anti-CD79B- VC-MMAE, RO-5541077Val-Cit (C)MMAEMicrotubulesAppr.DLBCLOn-going trialsIRR‡, gastrointestinal toxicity†, febrile neutropenia, anemia, thrombocytopenia, peripheral neuropathy, edema
Iladatuzumab vedotin [107]DCDS0780A, RO7032005Maleimidocaproyl- Val-Cit-PABC (C)MMAEMicrotubules1-No on-going trialsn.a.
CD205-MEN1309, OBT076 [174]N-succinimidyl- 4-(2-pyridyldithio) butanoate (C)DM4Microtubules1-On-going trialsn.a.
ROR1Zilovertamab vedotin [177–179, 182]VelosBio101, MK 2140, VLS-101Maleimidocaproyl-Val-Cit-para-aminobenzoate (C)MMAEMicrotubules2MCLOn-going trialsn.a.
-NBE-002 [180]Sortase A-mediated SMAC-technology (NC)PNU-159682DNA1-On-going trialsn.a.
Return to article view

based on http://adisinsight.springer.com and/or https://clinicaltrials.gov accessed in June 2022; -: none; : including corneal, extra corneal, and lacrimal disorders; : including nausea, vomiting, and diarrhea; : including headache, rash, back pain, vomiting, chills, nausea, dyspnea, pruritus, cough, and anaphylaxis; : including liver enzyme and/or bilirubin elevation; AEs: adverse events; Ala: alanine; Alias: international nonproprietary name; Appr.: approved; C: cleavable; Cit: citrulline; DM1: maytansinoid, mertansine; DM4: maytansinoid, ravtansine; IRR: infusion-related reaction; MMAF: monomethyl auristatin F; MCL: mantle cell lymphoma; n.a.: data not available; NC: not cleavable; PABC: p-amino benzyloxycarbonyl; PBD: pyrrolobenzodiazepine; ROR1: receptor tyrosine kinase-like orphan receptor 1; SMCC: succinimidyl trans-4-(maleimidylmethyl)cyclohexane-1-carboxylate; SPDB: N-succinimidyl 4-(2-pyridyldithio)butyrate; Val: valine